Category - Markets

Roth Capital Partners resumed coverage of Intec Pharma (NASDAQ:NTEC) with a “buy” rating and a price target of $8.50, citing a favorable risk/reward for the company’s Phase 3 Parkinson’s treatment, AP-CD/LD...

Ladenburg Thalmann initiated coverage of German-based Evotec (FSE:EVT) with a “buy” rating and price target of €22.50. The stock closed at €18.53 on Oct. 3. Evotec is a global drug discovery and services company that...

H.C. Wainwright raised its price target for STRATA Skin Sciences (NASDAQ:SSKN) to $5 from $3 after the company announced new clinical data that is expected to drive patient growth and retention. The stock closed at $3...

Stifel resumed coverage of Inovio Pharmaceuticals (NASDAQ:INO) with a “buy” rating and $8 price target, saying the implied risk/reward appears palatable. The stock closed at $5.35 on Oct. 1. Analyst Steven Willey writes...

Ladenburg Thalmann launched coverage of Oncolytics Biotech (NASDAQ:ONCY) with a “buy” rating and $22 price target. The stock closed at $3.86 on Sept. 28. Oncolytics is developing oncolytic virus (OV) therapy for cancer...

Ladenburg Thalmann initiated coverage of Neon Therapeutics (NASDAQ: NTGN) with a “buy” rating and $20 price target. The stock closed at $8.54 on Sept. 28. “We believe NEO-PV-01 enjoys a powerful first mover advantage in...

William Blair launched coverage of Restoration Robotics (NASDAQ:HAIR) with an “outperform” rating. The stock closed at $2.54 on Sept. 25. “With recent FDA approval of its latest-generation device, Restoration Robotics’...

Roth Capital Partners initiated coverage of Bionano Genomics (NASDAQ:BNGO) with a “buy” rating and $12 price target. The stock closed at $6.31 on Sept. 24. Bionano is a life sciences instrumentation company that offers...

H.C. Wainwright raised its price target for Verastem (NASDAQ:VSTM) to $15 from $10 after the FDA approved Verastem’s lead product, Copiktra, as the first PI3K-delta and P13K-gamma inhibitor for the treatment of third...

H.C. Wainwright launched coverage of Krystal Biotech (NASDAQ:KRYS) with a “buy” rating and $32 price target. The stock closed at $16.88 on Sept 21. “We believe the company has the potential to become a leader in the...